Boehringer Ingelheim's Vetmedin Becomes First USFDA-Approved Drug to Delay Heart Failure in Dogs

Published On 2026-01-20 15:35 GMT | Update On 2026-01-20 15:35 GMT

New Delhi: Pharmaceutical company Boehringer Ingelheim said on Monday the U.S. Food and Drug Administration had approved its chewable tablet, as the first drug to delay congestive heart failure in dogs with a type of early-stage heart disease. The approval covers dogs with a heart condition, known as myxomatous mitral valve disease, who show signs of heart enlargement but do not yet have symptoms.

The FDA said Vetmedin can now be used to slow the progression of the disease before dogs develop heart failure.

Also Read: U.S. FDA Grants Approval for Ranitidine Comeback

Vetmedin was first given conditional approval for this use in 2022, allowing it to be sold while the company collected more data. After three years of additional studies, Boehringer Ingelheim provided enough evidence for the FDA to grant full approval.

This marks the first time the FDA has fully approved a drug for animals after initially granting conditional approval under expanded rules designed to encourage new treatments for serious conditions.

Also Read: FDA Approves First At-Home Brain Neuromodulation Device for Depression

Heart disease is common in dogs, affecting about 10 percent of dogs in their lifetime, the company said. In a study, Vetmedin delayed the onset of congestive-heart-failure or cardiac-related death by 15.6 months.

Article Source : Reuters

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

sheeba farhat

Sheeba Farhat Joined Medical Dialogues in 2018 to report on the latest Education news. A Graduate of the University of Delhi, she specializes in covering stories related to Medical Education updates. For inquiries or further information, you can reach her at editorial@medicaldialogues.in.

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Boehringer Ingelheim's Vetmedin Becomes First USFDA-Approved Drug to Delay Heart Failure in Dogs

Similar News

Japanese Company Fails to Secure Indian Patent for Cancer Detection Using Nematodes

AstraZeneca Pharma India Slapped Rs 11.88 Cr Tax Adjustment for FY23, to Move ITAT

Sun Pharma Names Sana Shaikh as Head of Marketing

Syngene International, Bristol Myers Squibb Extend Strategic Collaboration Through 2035

Himachal Govt to Float Rs 100 Cr Tender for Direct Procurement of Medicines

Alcon India Gets Rs 25 Cr Tax Relief as ITAT Bengaluru Quashes Advertising, Marketing and Promotion Adjustments

CDSCO, DoP Told to Find Workable Solution on Revised Schedule M GMP Concerns